NUVB Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nuvation Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.80 |
| 52 Week High | US$4.16 |
| 52 Week Low | US$1.22 |
| Beta | 1.36 |
| 11 Month Change | 21.74% |
| 3 Month Change | -2.78% |
| 1 Year Change | 115.38% |
| 33 Year Change | -65.73% |
| 5 Year Change | n/a |
| Change since IPO | -71.13% |
Recent News & Updates
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Nov 20
Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Oct 21Recent updates
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Nov 20Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Oct 21Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Aug 08Is Nuvation Bio (NYSE:NUVB) A Risky Investment?
Aug 07Nuvation Bio: A Potentially Transformative Acquisition
Jun 20Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Mar 31Nuvation: Cash Is King, Science Is An Afterthought
Oct 03We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Feb 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nov 03Shareholder Returns
| NUVB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.5% | 1.6% | 2.2% |
| 1Y | 115.4% | 10.0% | 31.7% |
Return vs Industry: NUVB exceeded the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: NUVB exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| NUVB volatility | |
|---|---|
| NUVB Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NUVB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NUVB's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 203 | David Hung | www.nuvationbio.com |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Nuvation Bio Inc. Fundamentals Summary
| NUVB fundamental statistics | |
|---|---|
| Market cap | US$942.39m |
| Earnings (TTM) | -US$532.28m |
| Revenue (TTM) | US$2.16m |
435.9x
P/S Ratio-1.8x
P/E RatioIs NUVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUVB income statement (TTM) | |
|---|---|
| Revenue | US$2.16m |
| Cost of Revenue | US$2.86m |
| Gross Profit | -US$700.00k |
| Other Expenses | US$531.58m |
| Earnings | -US$532.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.58 |
| Gross Margin | -32.38% |
| Net Profit Margin | -24,619.84% |
| Debt/Equity Ratio | 1.7% |
How did NUVB perform over the long term?
See historical performance and comparison